Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  PAO Group, Inc.    PAOG

PAO GROUP, INC.

(PAOG)
SummaryChartsNewsCompany 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

PAOG Announces Goldman Small Cap Research Update Scheduled Next Week

share with twitter share with LinkedIn share with facebook
09/02/2020 | 01:25pm EDT

Sandusky, Ohio--(Newsfile Corp. - September 2, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced an analyst research report update form Goldman Small Cap Research scheduled to be published next week on Tuesday, September 8, 2020.

The original Goldman Small Cap Research Update can be reviewed at:

Under The Radar CBD Pharma Player Could Offer Major Upside

PAOG recently executed two acquisitions as part of an overall business revitalization strategy bringing the company into the cannabis biopharmaceutical sector. The company acquired a cannabis cultivation business from Puration, Inc. (PURA). From Kali-Extracts (KALY), PAOG acquired a proprietary CBD extract derived from a patented extraction process and formulated for the treatment of respiratory disorders.

Earlier today, the company announced being reinstated to the OTC Markets "Current Information" reporting standard.

PAOG recently executed two acquisitions as part of an overall business revitalization strategy bringing the company into the cannabis biopharmaceutical sector. The company acquired a cannabis cultivation business from Puration, Inc. (PURA). From Kali-Extracts (KALY), PAOG acquired a proprietary CBD extract derived from a patented extraction process and formulated for the treatment of respiratory disorders.

Goldman Small Cap Research is anticipated to update a recently published analyst report now.

www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63102


© Newsfilecorp 2020
share with twitter share with LinkedIn share with facebook
All news about PAO GROUP, INC.
09/17PAOG Target, CBD Pharma Development, In Puerto Rico Could Get Boost From COVI..
NE
09/16PAOG Announces Agreement to Build Pharmaceutical Hemp Cultivar Facility on PU..
NE
09/15PAOG Advances RespRx Research Into International CBD Pharma Research Arena
NE
09/15PAOG Goes Global with CBD Pharmaceutical Research to Target $5.8 Billion Mark..
NE
09/14PAOG New Updates Toward Penetrating $5.8B Cannabis Pharmaceutical Market Comi..
NE
09/11PURA Announces Analyst Report Pertaining to Coming 1 for 1 Dividend
NE
09/08PAOG Rated Bullish And Given PPS Target In Updated Analyst Report Published T..
NE
09/02PAOG Announces Goldman Small Cap Research Update Scheduled Next Week
NE
More news
Chart PAO GROUP, INC.
Duration : Period :
PAO Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
James C. DiPrima Chief Executive & Financial Officer
Gary C. Bernard Medical Director